Currently, PD-L1 expression is determined by IHC, and specific scoring systems have been developed, considering the percentage of expression on tumor cells versus immune cells in the TME as a guide for anti-PD-1 and anti-PD-L1 therapies. This evidence concerns the gene PDCD1 and neoplasm.